Clinical trial
Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.
NCT00327522 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00327522 |
|---|---|
| Title | Safety and Immune Response Study of an Investigational Pneumococcal Vaccine. |
| Official title | An Open, Phase I/II Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 11PCV Vaccine Given as a 2-Dose Vaccination in Adults Aged 18-40 Years Old. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prophylactic Pneumococcal Diseases |
| Intervention type | Biological |
| Interventions | pneumococcal vaccine |
| Enrollment | 10 |
| Start date | Jun 1, 2006 |
| First posted | May 18, 2006 |
| Last update posted | Oct 13, 2008 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: